Lucitram (Trametinib) 2 Mg Tablet

Link Copied
Business Type Exporter, Supplier, Retailer
Strength 2 Mg
Packaging Box
Color White
Click to view more

Product Details

Composition
Trametinib Dimethyl Sulfoxide
Packaging Size
1 Blister Strip of 30 Tablets
Indication
Treatment Of Melanoma, Non-small Cell Lung Cancer, Anaplastic Thyroid Cancer
Formulation
Tablet
Usage
Single Agent Or In Combination With Dabrafenib
Place of Origin
India

COMPOSITION:

\\n

 

\\n

Each Tablet contains: 2.254 mg Trametinib dimethyl sulfoxide equivalent to Trametinib……………… 2mg

\\n

 

\\n

INDICATION: 

\\n

 

\\n

LuciTram is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.

\\n

 

\\n

LuciTram is indicated, in combination with dabrafenib, for:

\\n

 

\\n

· the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.

\\n

 

\\n

· the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations.

\\n

 

\\n

· the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation.

\\n

 

\\n

· the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.COMPOSITION:

\\n

 

\\n

Each Tablet contains: 2.254 mg Trametinib dimethyl sulfoxide equivalent to Trametinib……………… 2mg

\\n

 

\\n

INDICATION: 

\\n

 

\\n

LuciTram is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.

\\n

 

\\n

LuciTram is indicated, in combination with dabrafenib, for:

\\n

 

\\n

· the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.

\\n

 

\\n

· the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations.

\\n

 

\\n

· the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation.

\\n

 

\\n

· the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.COMPOSITION:

\\n

 

\\n

Each Tablet contains: 2.254 mg Trametinib dimethyl sulfoxide equivalent to Trametinib……………… 2mg

\\n

 

\\n

INDICATION: 

\\n

 

\\n

LuciTram is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.

\\n

 

\\n

LuciTram is indicated, in combination with dabrafenib, for:

\\n

 

\\n

· the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.

\\n

 

\\n

· the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations.

\\n

 

\\n

· the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation.

\\n

 

\\n

· the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.

Yes! I am interested

Looking for "Lucitram (Trametinib) 2 Mg Tablet" ?

Pack

Explore More Products



Close

Raise your Query

Hi! Simply click below and type your query.

Our experts will reply you very soon.

WhatsApp Us